7 Stocks Worth Buying the Dip in Now... Or At Least Adding to Your Watchlist

Advanced Micro Devices reported Q1 2026 results on Tuesday after the close. Disney reported its 2026  first-quarter results before today’s open. They were both very good.

Unsurprisingly, the S&P 500 futures and both stocks were up in pre-market trading. Investors should expect a good day unless President Trump decides to ratchet up the war with Iran. 

To add to the good vibes, the S&P 500 closed yesterday’s trading at another record close at 7,259.22. 

As a result of the record high, there were 192 new 52-week highs on the NYSE and 427 on the Nasdaq Composite. Valuation multiples continue to rise, seemingly, unabated.  

Surprisingly, there were some new 52-week lows on both the NYSE (45) and the Nasdaq (111). Of the 156 new 52-week lows, there were 17 stocks with share prices of $100 or higher.

These seven have the highest share prices and are worth buying or at least putting on your watchlist. 

Home Depot (HD)

Home Depot (HD) hit a new 52-week low of $310.40, the 14th of the past 12 months. Its shares are down 12.8% in the past year. 

Home Depot is the undisputed leader in home improvement in the U.S. Therein lies the rub: When the real estate markets are cooking, HD can do no wrong. When they’re awful, as they are right now, same-store sales are flat to negative. Unavoidable. 

The big reason to own right now?

Get paid a nice dividend (3% yield) while it builds a substantial PRO business -- its $1.2 trillion total addressable market -- to complement the more cyclical and economically influenced DIY market.  

Kinsale Capital Group (KNSL)

Kinsale Capital Group (KNSL) hit a new 52-week low of $300.23, the 26th of the past 12 months. Its shares are down 33.1% in the past year. 

Anyone who’s followed the insurance industry in 2026 knows that it’s been a tough year for growth, especially in the ultra-competitive property & casualty market. That’s not where Kinsale competes. It underwrites specialty risks for small- and mid-sized businesses. They’ve been hurt by tariffs. 

Known for its disciplined underwriting, its combined ratio, which indicates underwriting profitability, was 77.4% in Q1 2026, 470 basis points higher than a year ago. Lower is definitely better. This led to a return on equity of 24.0%, 150 basis points higher than a year ago.

It pays to have disciplined underwriting in times of low or no premium growth.  

Stryker (SYK)

Stryker (SYK) hit a new 52-week low of $290.17, the 21st of the past 12 months. Its shares are down 22.6% in the past year. 

If you invested in Stryker five years ago, you’re sitting on an underwhelming annualized total return of just 4.2%. It has done little for investors despite continued growth. 

On April 30, despite a mediocre first quarter, Stryker maintained its revenue and earnings-per-share guidance. It expects organic revenue growth of 8.8% in 2026, along with EPS of $15. It trades at less than 20 times that estimate. Its forward P/E hasn’t been this low since 2018.  

McDonald’s (MCD)

McDonald’s (MCD) hit a new 52-week low of $283.02, the 13th of the past 12 months. Its shares are down 9.7% in the past year. 

Every time I walk to my local Starbucks (SBUX) at six in the morning, I ironically walk past a big billboard for McDonald’s $5 value meals. I personally don’t go to McDonald’s often, but I could see why someone would. You can’t get a gallon of gas for $5 in some places in America. Value and affordability go together like PB&J. It’s smart positioning.

It reports Q1 2026 results tomorrow. It’s expected to earn $2.75 a share with 8.9% revenue growth to $6.49 billion. It’s hard to imagine in this economy and their value offerings that it doesn’t deliver better-than-expected results. 

Either way, it’s hard not to like a business that generates annual free cash flow in excess of $7 billion despite more than $3.4 billion in capital expenditures.

As restaurant stocks and cash flow go, it remains in a field of its own.  

Steris (STE)

Steris (STE) hit a new 52-week low of $209.61, the 7th of the past 12 months. Its shares are down 5.1% in the past year. 

Speaking of free cash flow, the infection prevention specialist should exceed or come very close to $1 billion in FCF in fiscal 2026 (March. In the 12 months ended Dec. 31, 2025, it was $917 million, converting every dollar of income into $1.30 in free cash flow. 

Admittedly, I’m not an expert on Steris’s business. Of the 8 analysts covering STE, 5 rate it a Buy (4.25 out of 5), with a $287.33 target price. 

With nearly 10% annual revenue growth and 20% operating earnings growth, it will be able to deliver consistent dividend growth and share repurchases for years to come. 

Pool (POOL)

Pool (POOL) hit a new 52-week low of $186.94, the 29th of the past 12 months. Its shares are down 38.9% in the past year. 

Once upon a time, this company could do no wrong. Then life got expensive, and pools, especially building new ones, became secondary to keeping the family finances above water. 

Considered the world’s largest distributor of pool products, the company’s two busiest quarters are Q2 and Q3. In 2019 (pre-COVID), its combined sales for the two quarters were $2.02 billion. By 2022, that number was 82% higher at $3.67 billion. 

That’s darn good three-year growth for what is probably considered semi-discretionary revenue. Since then, sales have declined slightly and plateaued at around $3.2 billion. 

At the end of the day, while it’s lost out on a fair bit of new construction-related business, the recurring nature of servicing existing pools ensures that revenues don’t fall off a cliff like some industries. 

The downside is that it no longer converts $1 of income into more than a dollar of free cash flow. The upside? Its return on capital remains well into double digits.    

UFP Technologies (UFPT)

UFP Technologies (UFPT)  hit a new 52-week low of $173.86, the 10th of the past 12 months. Its shares are down 7.6% in the past year. 

The contract manufacturer for single-use medical devices serves an important role in the healthcare industry. That’s led to a healthy 5-year gain of nearly 300% for UFPT stock.  

What do they say about “slow and steady wins the race.” The stock really started to take off at the beginning of COVID in 2020. 

UFP reported strong Q1 2026 earnings results on Monday, including EPS of $2.48, 30 cents above the Zacks consensus estimate. Its medical market sales increased by 5.9% in the quarter to $143.4 million, or 93% of sales. 

While its share price has lagged in the past year, its focus on the medical market should help it remain profitable and healthy over the long haul.